Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma

被引:3
|
作者
Shi, Zhong-Xing [1 ]
Li, Chang -Fu [2 ]
Zhao, Li-Feng [3 ]
Sun, Zhong-Qi [4 ]
Cui, Li -Ming [1 ]
Xin, Yan-Jie [4 ]
Wang, Dong-Qing [1 ]
Kang, Tan-Rong [1 ]
Jiang, Hui-Jie [4 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Intervent Radiol, Harbin 150086, Peoples R China
[2] Daqing Longnan Hosp, Dept Digest Med, Daqing 163453, Peoples R China
[3] Daqing Longnan Hosp, Dept Radiol, Daqing 163453, Peoples R China
[4] Harbin Med Univ, Affiliated Hosp 2, Dept Radiol, Harbin 150086, Peoples R China
关键词
Hepatocellular carcinoma; Transarterial chemoembolization; Radiomics; Treatment response; Prediction; PROGNOSIS;
D O I
10.1016/j.hbpd.2023.06.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: According to clinical practice guidelines, transarterial chemoembolization (TACE) is the standard treatment modality for patients with intermediate -stage hepatocellular carcinoma (HCC). Early prediction of treatment response can help patients choose a reasonable treatment plan. This study aimed to investigate the value of the radiomic-clinical model in predicting the efficacy of the first TACE treatment for HCC to prolong patient survival. Methods: A total of 164 patients with HCC who underwent the first TACE from January 2017 to September 2021 were analyzed. The tumor response was assessed by modified response evaluation criteria in solid tumors (mRECIST), and the response of the first TACE to each session and its correlation with overall survival were evaluated. The radiomic signatures associated with the treatment response were identified by the least absolute shrinkage and selection operator (LASSO), and four machine learning models were built with different types of regions of interest (ROIs) (tumor and corresponding tissues) and the model with the best performance was selected. The predictive performance was assessed with receiver operating characteristic (ROC) curves and calibration curves. Results: Of all the models, the random forest (RF) model with peritumor ( + 10 mm) radiomic signatures had the best performance [area under ROC curve (AUC) = 0.964 in the training cohort, AUC = 0.949 in the validation cohort]. The RF model was used to calculate the radiomic score (Rad-score), and the optimal cutoff value (0.34) was calculated according to the Youden's index. Patients were then divided into a high -risk group (Rad-score > 0.34) and a low -risk group (Rad-score <= 0.34), and a nomogram model was successfully established to predict treatment response. The predicted treatment response also allowed for significant discrimination of Kaplan -Meier curves. Multivariate Cox regression identified six independent prognostic factors for overall survival, including male [hazard ratio (HR) = 0.500, 95% confidence interval (CI): 0.260-0.962, P = 0.038], alpha-fetoprotein (HR = 1.003, 95% CI: 1.002-1.004, P < 0.001), alanine aminotransferase (HR = 1.003, 95% CI: 1.0 01-1.0 05, P = 0.025), performance status (HR = 2.400, 95% CI: 1.20 0-4.80 0, P = 0.013), the number of TACE sessions (HR = 0.870, 95% CI: 0.780-0.970, P = 0.012) and Rad-score (HR = 3.480, 95% CI: 1.416-8.552, P = 0.007). Conclusions: The radiomic signatures and clinical factors can be well -used to predict the response of HCC patients to the first TACE and may help identify the patients most likely to benefit from TACE. (c) 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 50 条
  • [1] Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma
    ZhongXing Shi
    ChangFu Li
    LiFeng Zhao
    ZhongQi Sun
    LiMing Cui
    YanJie Xin
    DongQing Wang
    TanRong Kang
    HuiJie Jiang
    Hepatobiliary & Pancreatic Diseases International, 2024, 23 (04) : 361 - 369
  • [2] Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma
    ZhongXing Shi
    ChangFu Li
    LiFeng Zhao
    ZhongQi Sun
    LiMing Cui
    YanJie Xin
    DongQing Wang
    TanRong Kang
    HuiJie Jiang
    Hepatobiliary & Pancreatic Diseases International, 2024, (04) : 361 - 369
  • [3] Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization
    Jia, Fei
    Wu, Baolin
    Yan, Ruifang
    Li, Lei
    Wang, Kaiyu
    Han, Dongming
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2020, 52 (06) : 1657 - 1667
  • [4] Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
    Chen, Shuling
    Peng, Zhenwei
    Zhang, Yaojun
    Chen, Minshan
    Li, Jiaping
    Guo, Rongping
    Li, Jiali
    Li, Bin
    Mei, Jie
    Feng, Shiting
    Kuang, Ming
    RADIOLOGY, 2021, 298 (03) : 680 - 692
  • [5] Predicting the Initial Treatment Response to Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma by the Integration of Radiomics and Deep Learning
    Peng, Jie
    Huang, Jinhua
    Huang, Guijia
    Zhang, Jing
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Zhou, Qunfang
    Tuo, Fei
    Li, Ruixia
    Wang, Xiaohui
    Wang, Juncheng
    Huang, Zhimei
    Chen, Minshan
    Huang, Jinhua
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Adjuvant transarterial chemoembolization for intermediate-stage hepatocellular carcinoma with microvascular invasion
    Wang, Xiao-Hui
    Zhou, Qun-Fang
    Wang, Chen-Meng
    Xiang, Cai-Ling
    Song, Ying-Hui
    Li, Shao-Qiang
    Chen, Min-Shan
    Xiang, Shuang-Lin
    Liu, Chang-Jun
    Mao, Xian-Hai
    BRITISH JOURNAL OF SURGERY, 2023, 110 (08) : 913 - 916
  • [8] Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma
    Chen, Shuling
    Jin, Huilin
    Dai, Zihao
    Wei, Mengchao
    Xiao, Han
    Su, Tianhong
    Li, Bin
    Liu, Xin
    Wang, Yu
    Li, Jiaping
    Shen, Shunli
    Zhou, Qi
    Peng, Baogang
    Peng, Zhenwei
    Peng, Sui
    CANCER MEDICINE, 2019, 8 (04): : 1530 - 1539
  • [9] Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
    Kim, Jun Young
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Choi, Gyu-Seong
    Saleh, Aldosri Meshal
    Joh, Jae-Won
    Cho, Sung Ki
    Shin, Sung Wook
    Carriere, Keumhee Chough
    Ahn, Joong Hyun
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    CLINICAL AND MOLECULAR HEPATOLOGY, 2016, 22 (02) : 250 - 258
  • [10] New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization
    Kim, Jin Hyoung
    Shim, Ju Hyun
    Lee, Han Chu
    Sung, Kyu-Bo
    Ko, Heung-Kyu
    Ko, Gi-young
    Gwon, Dong Il
    Kim, Jong Woo
    Lim, Yung-Suk
    Park, Seong Ho
    LIVER INTERNATIONAL, 2017, 37 (12) : 1861 - 1868